# Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

> **NCT00056550** · PHASE3 · COMPLETED · sponsor: **rEVO Biologics** · enrollment: 14 (actual)

## Conditions studied

- Antithrombin Deficiency, Congenital

## Interventions

- **BIOLOGICAL:** Recombinant Human Antithrombin (rhAT)

## Key facts

- **NCT ID:** NCT00056550
- **Lead sponsor:** rEVO Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2012-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056550, "Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00056550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*